Table 2.
Summary of treatment response
| Chemoimmunotherapy group (n=341) | Radiomics analysis in chemoimmunotherapy group | Chemotherapy group (n=57) | |||
| Training set (n=174) |
Validation set 1 (n=39) | Validation set 2 (n=45) | |||
| ORR | 77.4% | 70.1% | 84.6% | 88.9% | 73.7% |
| DCR | 97.4% | 96.6% | 92.3% | 100.0% | 89.5% |
| Death | 25.5% | 26.4% | 43.6% | 4.4% | 42.1% |
| Follow-up time, median (95% CI), months |
12.1 (11.0 to 13.2) | 12.4 (11.1 to 13.7) | 15.3 (13.6 to 16.9) | 7.1 (6.0 to 8.2) | 11.8 (8.9 to 14.7) |
| PFS, median (95% CI), months | 7.1 (6.6 to 7.7) | 6.9 (6.2 to 7.7) | 6.9 (4.7 to 9.2) | 8.1 (6.3 to 9.9) | 5.9 (5.1 to 6.7) |
| OS, median (95% CI), months | NR | NR | 19.1 (9.9 to 28.3) | NR | 13.7 (8.9 to 18.5) |
| 6-month PFS (%) | 60.7% | 60.3% | 53.8% | 66.1% | 45.5% |
| 9-month PFS (%) | 38.2% | 36.0% | 41.0% | 44.4% | 13.0% |
| 12-month PFS (%) | 28.3% | 25.6% | 38.3% | 22.4% | 4.3% |
| 12-month OS (%) | 75.0% | 73.2% | 62.6% | 86.4% | 59.1% |
| 18-month OS (%) | 58.5% | 60.7% | 51.6% | 86.4% | 30.8% |
DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.